«We know that 70 - 75 percent of glioblastoma patients undergo surgery for tumor debulking, and we have previously shown that MSCs encapsulated in biocompatible gels can be used as therapeutic agents in a mouse model that mimics this debulking,» he continued. (sciencedaily.com)
They are also getting skin cells from glioblastoma patients to make sure the new method works for the people they hope to help, he says. (sciencemag.org)
Increased levels of STK17A are correlated with shorter survival time for glioblastoma patients. (sciencedaily.com)